Novartis 3Q 3Q Revenues: $11.1 billion (+3%) 3Q Earnings: $2.1 billion (+1%) YTD Revenues: $31.3 billion (flat) YTD Earnings: $6.1 billion (-8%) Comments: Pharmaceutical sales in the quarter were $7.2 billion (+8%). Diovan sales were $4.4 billion (+5% in local currencies), driven by expansion in Japan, which accounts for approximately 20% of sales. Exforge sales were $475 million (+81% lc). Tekturna/Rasilez sales were $202 million (+114% lc). Gleevec/Glivec sales were $2.9 billion...